Dear Researchers,

The library will operate on a duty schedule between 22 December 2025 and 4 January 2026. During this period, it will be possible to upload publications, but all other services will be suspended.

Thank you for your understanding.

Enyedi Enikő Edit

Publication list

Tudóstér co-authors statistics filterable publication list

Export to RIS (EndNote, Mendeley, RefWorks, Zotero etc.)

Upload publications

Request certified publication list

Uploaded publications:

Publications in DEA:

OA:

Date range:

2020-2025

2025

Szabó, A. Á., Enyedi, E. E., Pintér, T. B., Mányiné Siket, I., Váradi, C., Bányai, E., Tóth, A., Papp, Z., Fagyas, M.: Interference-Free Measurement of Urinary Angiotensin-Converting Enzyme (ACE) Activity: Diagnostic and Therapeutic Monitoring Implications.
Biomedicines. 13 (10), 1-17, (article identifier: 2528), 2025.

doi DEA WoS Scopus

Journal metrics:

Q1 Biochemistry, Genetics and Molecular Biology (miscellaneous) (2024)

Q1 Medicine (miscellaneous) (2024)

2024

Enyedi, E. E., Petukhov, P. A., Kozuch, A. J., Dudek, S., Tóth, A., Fagyas, M., Danilov, S. M.: ACE Phenotyping in Human Blood and Tissues: revelation of ACE Outliers and Sex Differences in ACE Sialylation.
Biomedicines. 12 (5), 1-17, (article identifier: 940), 2024.

doi DEA WoS Scopus

Journal metrics:

Q1 Biochemistry, Genetics and Molecular Biology (miscellaneous)

Q1 Medicine (miscellaneous)

Szabó, A. Á., Enyedi, E. E., Altorjay, I., Hajnal, P., Pintér, T. B., Mányiné Siket, I., Váradi, C., Bányai, E., Tóth, A., Papp, Z., Fagyas, M.: Get reliable laboratory findings: how to recognize the deceptive effects of angiotensin-converting enzyme inhibitor therapy in the laboratory diagnostics of sarcoidosis?.
Clin. Chem. Lab. Med. 62 (7), 1393-1401, 2024.

doi DEA WoS Scopus

Journal metrics:

Q1 Biochemistry (medical)

Q2 Clinical Biochemistry

Q1 Medicine (miscellaneous)

2023

Nagy, A. C., Majer, R., Boczán, J., Sipka, S. i., Szabó, A. Á., Enyedi, E. E., Tatai, O., Fagyas, M., Papp, Z., Csiba, L., Tóth, A.: Enalapril Is Superior to Lisinopril in Improving Endothelial Function without a Difference in Blood-Pressure-Lowering Effects in Newly Diagnosed Hypertensives.
Biomedicines. 11 (12), 1-13, (article identifier: 3323), 2023.

doi DEA WoS Scopus

Journal metrics:

Q1 Biochemistry, Genetics and Molecular Biology (miscellaneous)

Q1 Medicine (miscellaneous)

2022

Fagyas, M., Nagy, B. J., Ráduly, A. P., Mányiné Siket, I., Mártha, L., Erdősi, G., Sipka, S. i., Enyedi, E. E., Szabó, A. Á., Pólik, Z., Kappelmayer, J., Papp, Z., Borbély, A., Szabó, T., Balla, J., Balla, G., Bai, P., Bácsi, A., Tóth, A.: The majority of severe COVID-19 patients develop anti-cardiac autoantibodies.
GeroScience. 44, 2347-2360, 2022.

doi DEA WoS Scopus

Journal metrics:

Q1 Aging

Q1 Cardiology and Cardiovascular Medicine

D1 Complementary and Alternative Medicine

Q1 Geriatrics and Gerontology

D1 Veterinary (miscellaneous)

2021

Csongrádi, A., Altorjay, I., Fülöp, G. Á., Enyedi, A., Enyedi, E. E., Hajnal, P., Takács, I., Tóth, A., Papp, Z., Fagyas, M.: Chitotriosidase gene polymorphisms and mutations limit the determination of chitotriosidase expression in sarcoidosis.
Clin. Chim. Acta. 513, 50-56, 2021.

doi DEA WoS Scopus

Journal metrics:

Q2 Biochemistry

Q2 Biochemistry (medical)

Q1 Clinical Biochemistry

Q1 Medicine (miscellaneous)

2020